David Z I Cherney

List of Publications by Year
in descending order

Version: 2024-02-01

199 papers	12,917 citations	36303 51 h-index	26613 107 g-index
201 all docs	201 docs citations	201 times ranked	8716 citing authors

#	Article	IF	Citations
1	Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus. Circulation, 2014, 129, 587-597.	1.6	1,045
2	Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus. Circulation, 2016, 134, 752-772.	1.6	932
3	Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. New England Journal of Medicine, 2020, 383, 1425-1435.	27.0	927
4	Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. New England Journal of Medicine, 2021, 384, 129-139.	27.0	662
5	Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes. JAMA Cardiology, 2021, 6, 148.	6.1	625
6	The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovascular Diabetology, 2014, 13, 28.	6.8	381
7	Sodium Glucose Cotransporter-2 Inhibition in Heart Failure. Circulation, 2017, 136, 1643-1658.	1.6	340
8	Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 610-621.	11.4	301
9	Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney International, 2018, 94, 26-39.	5.2	262
10	Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials. Diabetes Care, 2018, 41, 2560-2569.	8.6	239
11	The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. Diabetologia, 2018, 61, 2098-2107.	6.3	234
12	Sodium-Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open-Label Proof-of-Concept Trial. Diabetes Care, 2014, 37, 1480-1483.	8.6	211
13	Evaluation of Glomerular Hemodynamic Function by Empagliflozin in Diabetic Mice Using In Vivo Imaging. Circulation, 2019, 140, 303-315.	1.6	202
14	Pooled analysis of Phase III trials indicate contrasting influences of renal function on bloodÂpressure, body weight, and HbA1c reductions with empagliflozin. Kidney International, 2018, 93, 231-244.	5.2	174
15	Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial. Nephrology Dialysis Transplantation, 2020, 35, 274-282.	0.7	168
16	Efficacy of Ertugliflozin on Heart Failureâ€"Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease. Circulation, 2020, 142, 2205-2215.	1.6	156
17	Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial. Lancet Diabetes and Endocrinology,the, 2020, 8, 582-593.	11.4	155
18	The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes. Diabetologia, 2016, 59, 1860-1870.	6.3	148

#	Article	IF	Citations
19	Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus. American Journal of Physiology - Renal Physiology, 2015, 308, F77-F83.	2.7	143
20	Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration. Diabetologia, 2014, 57, 2599-2602.	6.3	136
21	Management of patients with hypertensive urgencies and emergencies. Journal of General Internal Medicine, 2002, 17, 937-945.	2.6	135
22	The Metabolodiuretic Promise of Sodium-Dependent Glucose Cotransporter 2 Inhibition. JAMA Cardiology, 2017, 2, 939.	6.1	135
23	Sodiumâ€“glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy. Current Opinion in Nephrology and Hypertension, 2015, 24, 96-103.	2.0	134
24	Uric Acid Lowering to Prevent Kidney Function Loss in Diabetes: The Preventing Early Renal Function Loss (PERL) Allopurinol Study. Current Diabetes Reports, 2013, 13, 550-559.	4.2	127
25	Renal hyperfiltration related to diabetes mellitus and obesity in human disease. World Journal of Diabetes, 2012, 3, 1.	3.5	126
26	Impact of Renin Angiotensin System Modulation on the Hyperfiltration State in Type 1 Diabetes. Journal of the American Society of Nephrology: JASN, 2006, 17, 1703-1709.	6.1	117
27	Characterization and implications of the initial estimated glomerular filtration rate â€˜dipâ€™ upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. Kidney International, 2021, 99, 750-762.	5.2	111
28	The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. Nephrology Dialysis Transplantation, 2020, 35, 1700-1711.	0.7	107
29	Sodiumâ€“glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis. Kidney International, 2016, 89, 524-526.	5.2	105
30	Uric Acid as a Biomarker and a Therapeutic Target in Diabetes. Canadian Journal of Diabetes, 2015, 39, 239-246.	0.8	103
31	Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial. Diabetologia, 2021, 64, 1256-1267.	6.3	103
32	Early diabetic nephropathy in type 1 diabetes. Current Opinion in Endocrinology, Diabetes and Obesity, 2014, 21, 279-286.	2.3	101
33	Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials. Circulation, 2022, 145, 1460-1470.	1.6	97
34	Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes. Kidney International, 2014, 86, 1057-1058.	5.2	93
35	CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis. Canadian Journal of Cardiology, 2020, 36, 159-169.	1.7	89
36	The Effect of Cyclooxygenase-2 Inhibition on Renal Hemodynamic Function in Humans With Type 1 Diabetes. Diabetes, 2008, 57, 688-695.	0.6	84

#	Article	IF	Citations
37	Effect of Direct Renin Inhibition on Renal Hemodynamic Function, Arterial Stiffness, and Endothelial Function in Humans With Uncomplicated Type 1 Diabetes. Diabetes Care, 2010, 33, 361-365.	8.6	84
38	Dipeptidyl Peptidase 4 Inhibition Stimulates Distal Tubular Natriuresis and Increases in Circulating SDF-1Î±1-67 in Patients With Type 2 Diabetes. Diabetes Care, 2017, 40, 1073-1081.	8.6	82
39	Reference Values for Pulse Wave Doppler and Tissue Doppler Imaging in Pediatric Echocardiography. Circulation: Cardiovascular Imaging, 2015, 8, e002167.	2.6	77
40	Analysis from the EMPA-REG OUTCOMEÂ® trialÂindicates empagliflozin may assist in preventingÂtheÂprogression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics. Kidney International, 2019, 96, 489-504.	5.2	77
41	The New Biology of Diabetic Kidney Diseaseâ€"Mechanisms and Therapeutic Implications. Endocrine Reviews, 2020, 41, 202-231.	20.1	77
42	Preventing CKD in Developed Countries. Kidney International Reports, 2020, 5, 263-277.	0.8	72
43	Gender differences in renal responses to hyperglycemia and angiotensin-converting enzyme inhibition in diabetes. Kidney International, 2005, 68, 1722-1728.	5.2	71
44	Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study. American Journal of Physiology - Renal Physiology, 2018, 314, F412-F422.	2.7	68
45	Renal Hyperfiltration Is a Determinant of Endothelial Function Responses to Cyclooxygenase 2 Inhibition in Type 1 Diabetes. Diabetes Care, 2010, 33, 1344-1346.	8.6	66
46	Clinical Implications of an Acute Dip in eGFR after SGLT2 Inhibitor Initiation. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1278-1280.	4.5	65
47	Early changes in cardiovascular structure and function in adolescents with type 1 diabetes. Cardiovascular Diabetology, 2016, 15, 31.	6.8	64
48	Hyperfiltration and effect of nitric oxide inhibition on renal and endothelial function in humans with uncomplicated type 1 diabetes mellitus. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2012, 303, R710-R718.	1.8	60
49	Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations. Kidney International Reports, 2022, 7, 1463-1476.	0.8	59
50	Chronic Kidney Disease in Diabetes. Canadian Journal of Diabetes, 2018, 42, S201-S209.	0.8	57
51	Renal hyperfiltration defined by high estimated glomerular filtration rate: A risk factor for cardiovascular disease and mortality. Diabetes, Obesity and Metabolism, 2019, 21, 2368-2383.	4.4	56
52	Use of Canagliflozin in Kidney Transplant Recipients for the Treatment of Type 2 Diabetes: A Case Series. Diabetes Care, 2017, 40, e75-e76.	8.6	55
53	The Acute Effect of Clamped Hyperglycemia on the Urinary Excretion of Inflammatory Cytokines/Chemokines in Uncomplicated Type 1 Diabetes: A pilot study. Diabetes Care, 2011, 34, 177-180.	8.6	53
54	A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function. Kidney International, 2022, 101, 174-184.	5.2	53

#	Article	IF	Citations
55	Insights into the Regulation of Renal Hemodynamic Function in Diabetic Mellitus. Current Diabetes Reviews, 2008, 4, 280-290.	1.3	51
56	Use of Sodium Glucose Cotransporter 2 Inhibitors in the Hands of Cardiologists. Circulation, 2016, 134, 1915-1917.	1.6	50
57	The Impact of Sotagliflozin on Renal Function, Albuminuria, Blood Pressure, and Hematocrit in Adults With Type 1 Diabetes. Diabetes Care, 2019, 42, 1921-1929.	8.6	47
58	Urinary adenosine excretion in type 1 diabetes. American Journal of Physiology - Renal Physiology, 2017, 313, F184-F191.	2.7	46
59	Cystatin C and acute changes in glomerular filtration rate. Clinical Nephrology, 2012, 78, 64-75.	0.7	45
60	The Effect of Direct Renin Inhibition Alone and in Combination With ACE Inhibition on Endothelial Function, Arterial Stiffness, and Renal Function in Type 1 Diabetes. Diabetes Care, 2012, 35, 2324-2330.	8.6	44
61	Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: from biomarkers to clinical outcomes in heart failure and diabetic kidney disease. Metabolism: Clinical and Experimental, 2022, 126, 154918.	3.4	42
62	Renal hemodynamic effect of cyclooxygenase 2 inhibition in young men and women with uncomplicated type 1 diabetes mellitus. American Journal of Physiology - Renal Physiology, 2008, 294, F1336-F1341.	2.7	41
63	Hyperfiltration, urinary albumin excretion, and ambulatory blood pressure in adolescents with Type 1 diabetes mellitus. American Journal of Physiology - Renal Physiology, 2018, 314, F667-F674.	2.7	41
64	Preventing Early Renal Loss in Diabetes (PERL) Study: A Randomized Double-Blinded Trial of Allopurinolâ€"Rationale, Design, and Baseline Data. Diabetes Care, 2019, 42, 1454-1463.	8.6	39
65	Effect of Protein Kinase Cî² Inhibition on Renal Hemodynamic Function and Urinary Biomarkers in Humans With Type 1 Diabetes: A Pilot Study. Diabetes Care, 2009, 32, 91-93.	8.6	38
66	Renin-angiotensin-aldosterone system activation in long-standing type 1 diabetes. JCI Insight, 2018, 3, .	5.0	38
67	Neuropathy and presence of emotional distress and depression in longstanding diabetes: Results from the Canadian study of longevity in type 1 diabetes. Journal of Diabetes and Its Complications, 2017, 31, 1318-1324.	2.3	37
68	Novel therapies for diabetic kidney disease. Kidney International Supplements, 2018, 8, 18-25.	14.2	37
69	Atherosclerosis and Microvascular Complications: Results From the Canadian Study of Longevity in Type 1 Diabetes. Diabetes Care, 2018, 41, 2570-2578.	8.6	37
70	Sodium-Glucose Cotransporter 2 Inhibition in Type 1 Diabetes: Simultaneous Glucose Lowering and Renal Protection?. Canadian Journal of Diabetes, 2014, 38, 356-363.	0.8	35
71	The Gomez equations and renal hemodynamic function in kidney disease research. American Journal of Physiology - Renal Physiology, 2016, 311, F967-F975.	2.7	35
72	Sodium glucose cotransporter 2 inhibition and renal ischemia: implications for future clinicalÂtrials. Kidney International, 2018, 94, 459-462.	5.2	35

#	Article	IF	Citations
73	Serum Uromodulin Predicts Less Coronary Artery Calcification and Diabetic Kidney Disease Over 12 Years in Adults With Type 1 Diabetes: The CACTI Study. Diabetes Care, 2019, 42, 297-302.	8.6	34
74	Relative Hypoxia and Early Diabetic Kidney Disease in Type 1 Diabetes. Diabetes, 2020, 69, 2700-2708.	0.6	34
75	The relationship between urinary renin-angiotensin system markers, renal function, and blood pressure in adolescents with type 1 diabetes. American Journal of Physiology - Renal Physiology, 2017, 312, F335-F342.	2.7	33
76	Effects of ertugliflozin on renal function over 104Âweeks of treatment: a post hoc analysis of two randomised controlled trials. Diabetologia, 2020, 63, 1128-1140.	6.3	33
77	Renal Hyperfiltration and Arterial Stiffness in Humans With Uncomplicated Type 1 Diabetes. Diabetes Care, 2010, 33, 2068-2070.	8.6	32
78	New and old agents in the management of diabetic nephropathy. Current Opinion in Nephrology and Hypertension, 2016, 25, 232-239.	2.0	31
79	Impact of Cardio-Renal-Metabolic Comorbidities on Cardiovascular Outcomes and Mortality in Type 2 Diabetes Mellitus. American Journal of Nephrology, 2020, 51, 74-82.	3.1	31
80	We Can Finally Stop Worrying About SGLT2 Inhibitors and Acute Kidney Injury. American Journal of Kidney Diseases, 2020, 76, 454-456.	1.9	30
81	Efficacy and safety of sotagliflozin in patients with type <scp>2</scp> diabetes and severe renal impairment. Diabetes, Obesity and Metabolism, 2021, 23, 2632-2642.	4.4	30
82	Cardiovascular disease guideline adherence and self-reported statin use in longstanding type 1 diabetes: results from the Canadian study of longevity in diabetes cohort. Cardiovascular Diabetology, 2016, 15, 14.	6.8	29
83	Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors inÂhyperfiltering people with type 1 diabetes andÂpeople with type 2 diabetes and normal kidney function. Kidney International, 2020, 97, 631-635.	5.2	29
84	Renal and Vascular Effects of Uric Acid Lowering in Normouricemic Patients With Uncomplicated Type 1 Diabetes. Diabetes, 2017, 66, 1939-1949.	0.6	28
85	Diurnal Glycemic Patterns during an 8-Week Open-Label Proof-of-Concept Trial of Empagliflozin in Type 1 Diabetes. PLoS ONE, 2015, 10, e0141085.	2.5	28
86	Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial. Diabetologia, 2022, 65, 1085-1097.	6.3	28
87	Relationship between serum inflammatory markers and vascular function in a cohort of adolescents with type 1 diabetes. Cytokine, 2017, 99, 233-239.	3.2	27
88	Acute Effect of Empagliflozin on Fractional Excretion of Sodium and eGFR in Youth With Type 2 Diabetes. Diabetes Care, 2018, 41, e129-e130.	8.6	27
89	Antidiuretic Hormone and Serum Osmolarity Physiology and Related Outcomes: What Is Old, What Is New, and What Is Unknown?. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5406-5420.	3.6	27
90	Age is a determinant of acute hemodynamic responses to hyperglycemia and angiotensin II in humans with uncomplicated type 1 diabetes mellitus. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2010, 299, R206-R214.	1.8	26

#	Article	IF	Citations
91	Ertugliflozin and Slope of Chronic eGFR. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1345-1354.	4.5	26
92	Natural history and outcome of incarcerated abdominal hernias in peritoneal dialysis patients. Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis, 2004, 20, 86-9.	0.1	26
93	Prevalence of Insulin Pump Therapy and Its Association with Measures of Glycemic Control: Results from the Canadian Study of Longevity in Type 1 Diabetes. Diabetes Technology and Therapeutics, 2016, 18, 298-307.	4.4	25
94	Improvements in peripheral vascular function with vitamin D treatment in deficient adolescents with type 1 diabetes. Pediatric Diabetes, 2018, 19, 457-463.	2.9	24
95	Gradient of Risk and Associations With Cardiovascular Efficacy of Ertugliflozin by Measures of Kidney Function. Circulation, 2021, 143, 602-605.	1.6	24
96	Urinary ACE2 in healthy adults and patients with uncomplicated type 1 diabetes. Canadian Journal of Physiology and Pharmacology, 2014, 92, 703-706.	1.4	23
97	Perioperative Considerations for the Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes. Anesthesia and Analgesia, 2018, 126, 699-704.	2.2	23
98	A Big Win for Diabetic Kidney Disease: CREDENCE. Cell Metabolism, 2019, 29, 1024-1027.	16.2	23
99	Markers of Kidney Injury, Inflammation, and Fibrosis Associated With Ertugliflozin in Patients With CKD and Diabetes. Kidney International Reports, 2021, 6, 2095-2104.	0.8	23
100	Renal Hyperfiltration and Systemic Blood Pressure in Patients with Uncomplicated Type 1 Diabetes Mellitus. PLoS ONE, 2013, 8, e68908.	2.5	23
101	Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism, 2022, 24, 1829-1839.	4.4	23
102	Association Between Plasma Uric Acid Levels and Cardiorenal Function in Adolescents With Type 1 Diabetes. Diabetes Care, 2016, 39, 611-616.	8.6	22
103	Influence of sex on hyperfiltration in patients with uncomplicated type 1 diabetes. American Journal of Physiology - Renal Physiology, 2017, 312, F599-F606.	2.7	22
104	Antihyperglycemic agents as novel natriuretic therapies in diabetic kidney disease. American Journal of Physiology - Renal Physiology, 2018, 315, F1406-F1415.	2.7	22
105	The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients with Type 2 Diabetes CardioLink-6 trial. Nephrology Dialysis Transplantation, 2020, 35, 895-897.	0.7	22
106	Effect of Uric Acid-Lowering Agents on Cardiovascular Outcome in Patients With Heart Failure: A Systematic Review and Meta-Analysis of Clinical Studies. Angiology, 2020, 71, 315-323.	1.8	22
107	Changes in Cardiovascular Biomarkers Associated With the Sodiumâ€“Glucose Cotransporter 2 (SGLT2) Inhibitor Ertugliflozin in Patients With Chronic Kidney Disease and Type 2 Diabetes. Diabetes Care, 2021, 44, e45-e47.	8.6	22
108	The effect of sodium/glucose cotransporter 2 (SGLT2) inhibition on the urinary proteome. PLoS ONE, 2017, 12, e0186910.	2.5	21

#	Article	IF	Citations
109	Molecular regulation of the reninâ€“angiotensin system by sodiumâ€“glucose cotransporter 2 inhibition in type 1 diabetes mellitus. Diabetologia, 2019, 62, 1090-1093.	6.3	21
110	Bone mineral density in patients with longstanding type 1 diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes. Journal of Diabetes and Its Complications, 2019, 33, 107324.	2.3	21
111	What have we learned about renal protection from the cardiovascular outcome trials and observational analyses with SGLT2 inhibitors?. Diabetes, Obesity and Metabolism, 2020, 22, 55-68.	4.4	20
112	Kidney outcomes using a sustained â‰¥40% decline in <scp>eGFR</scp>: A metaâ€analysis of <scp>SGLT2</scp> inhibitor trials. Clinical Cardiology, 2021, 44, 1139-1143.	1.8	20
113	Effect of sodiumâ€“glucose cotransporter 2 inhibitors on hemoglobin and hematocrit levels in type 2 diabetes: a systematic review and meta-analysis. International Urology and Nephrology, 2022, 54, 827-841.	1.4	20
114	The Urinary Cytokine/Chemokine Signature of Renal Hyperfiltration in Adolescents with Type 1 Diabetes. PLoS ONE, 2014, 9, e111131.	2.5	18
115	No Need to Sugarcoat the Message: Is Cardiovascular RiskÂReduction From SGLT2ÂInhibition Related to Natriuresis?. American Journal of Kidney Diseases, 2016, 68, 349-352.	1.9	18
116	Plasma biomarkers improve prediction of diabetic kidney disease in adults with type 1 diabetes over a 12-year follow-up: CACTI study. Nephrology Dialysis Transplantation, 2018, 33, 1189-1196.	0.7	18
117	Evolution of Renal Hyperfiltration and Arterial Stiffness From Adolescence Into Early Adulthood in Type 1 Diabetes. Diabetes Care, 2011, 34, 1821-1826.	8.6	17
118	Diabetes Care Disparities in Long-standing Type 1 Diabetes in Canada and the U.S.: A Cross-sectional Comparison. Diabetes Care, 2018, 41, 88-95.	8.6	17
119	Sodium glucose cotransporter (SGLT)â€2 inhibitors: Do we need them for glucoseâ€lowering, for cardiorenal protection or both?. Diabetes, Obesity and Metabolism, 2019, 21, 24-33.	4.4	17
120	Changes in plasma and urine metabolites associated with empagliflozin in patients with type 1 diabetes. Diabetes, Obesity and Metabolism, 2021, 23, 2466-2475.	4.4	17
121	Cardiorenal mechanisms of action of glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors. Med, 2021, 2, 1203-1230.	4.4	17
122	Retinopathy and RAAS Activation: Results From the Canadian Study of Longevity in Type 1 Diabetes. Diabetes Care, 2019, 42, 273-280.	8.6	16
123	Renal Hemodynamic Function and RAAS Activation Over the Natural History of Type 1 Diabetes. American Journal of Kidney Diseases, 2019, 73, 786-796.	1.9	15
124	The relationships between markers of tubular injury and intrarenal haemodynamic function in adults with and without type 1 diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 575-583.	4.4	15
125	Sex Differences in Renal Responses to Hyperglycemia, <scp>l</scp>-Arginine, and <scp>l</scp>-NMMA in Humans With Uncomplicated Type 1 Diabetes. Diabetes Care, 2013, 36, 1290-1296.	8.6	14
126	GLP-1R Agonists and Endothelial Dysfunction: More Than Just Glucose Lowering?. Diabetes, 2015, 64, 2319-2321.	0.6	14

#	Article	IF	Citations
127	Lower corneal nerve fibre length identifies diabetic neuropathy in older adults with diabetes: results from the Canadian Study of Longevity in Type 1 Diabetes. Diabetologia, 2017, 60, 2529-2531.	6.3	14
128	Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial. BMJ Open Diabetes Research and Care, 2021, 9, e002484.	2.8	14
129	The effect of aliskiren on urinary cytokine/chemokine responses to clamped hyperglycaemia in type 1 diabetes. Diabetologia, 2013, 56, 2308-2317.	6.3	13
130	Adiposity Impacts Intrarenal Hemodynamic Function in Adults With Long-standing Type 1 Diabetes With and Without Diabetic Nephropathy: Results From the Canadian Study of Longevity in Type 1 Diabetes. Diabetes Care, 2018, 41, 831-839.	8.6	13
131	Renal Angiotensinogen and Sodium-Glucose Cotransporter-2 Inhibition: Insights from Experimental Diabetic Kidney Disease. American Journal of Nephrology, 2019, 49, 328-330.	3.1	13
132	The Effect of Urine pH and Urinary Uric Acid Levels on the Development of Contrast Nephropathy. Kidney and Blood Pressure Research, 2020, 45, 131-141.	2.0	13
133	Kidney Effects of Empagliflozin in People with Type 1 Diabetes. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1715-1719.	4.5	13
134	Estimating GFR by Serum Creatinine, Cystatin C, and Î²2-Microglobulin in Older Adults: Results From the Canadian Study of Longevity in Type 1 Diabetes. Kidney International Reports, 2019, 4, 786-796.	0.8	12
135	Association between uric acid, renal haemodynamics and arterial stiffness over the natural history of type 1 diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 1388-1398.	4.4	12
136	Neurohormones, inflammatory mediators, and cardiovascular injury in the setting of heart failure. Heart Failure Reviews, 2020, 25, 685-701.	3.9	12
137	Discoveries from the study of longstanding type 1 diabetes. Diabetologia, 2021, 64, 1189-1200.	6.3	12
138	Hemodynamic and neurochemical determinates of renal function in chronic heart failure. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2016, 310, R167-R175.	1.8	11
139	Managing the Course of Kidney Disease in Adults With Type 2 Diabetes: From the Old to the New. Canadian Journal of Diabetes, 2018, 42, 325-334.	0.8	11
140	Cardiovascular Risk Reduction in PatientsÂWith Chronic Kidney Disease. Journal of the American College of Cardiology, 2018, 71, 2415-2418.	2.8	11
141	Dulaglutide and renal protection in type 2 diabetes. Lancet Diabetes and Endocrinology,the, 2018, 6, 588-590.	11.4	11
142	Transforming the Care of Patients with Diabetic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1590-1600.	4.5	11
143	Finerenoneâ€"A New Frontier in Renin-Angiotensin-Aldosterone System Inhibition in Diabetic Kidney Disease. American Journal of Kidney Diseases, 2021, 78, 309-311.	1.9	11
144	Fasting Blood Glucose-A Missing Variable for GFR-Estimation in Type 1 Diabetes?. PLoS ONE, 2014, 9, e96264.	2.5	11

#	Article	IF	Citations
145	Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: Results from <scp>DAPASALT</scp> and <scp>DIAMOND</scp>. Diabetes, Obesity and Metabolism, 2022, 24, 1578-1587.	4.4	11
146	Exploring Patient Preferences for Adjunct-to-Insulin Therapy in Type 1 Diabetes. Diabetes Care, 2019, 42, 1716-1723.	8.6	10
147	Renal haemodynamic and protective effects of renoactive drugs in type 2 diabetes: Interaction with SGLT2 inhibitors. Nephrology, 2021, 26, 377-390.	1.6	10
148	Cardiorenal Protection in Diabetic Kidney Disease. Endocrinology and Metabolism, 2021, 36, 256-269.	3.0	10
149	The angiotensin II receptor type 2 polymorphism influences haemodynamic function and circulating RAS mediators in normotensive humans. Nephrology Dialysis Transplantation, 2010, 25, 4093-4096.	0.7	9
150	Systemic hemodynamic function in humans with type 1 diabetes treated with protein kinase CÎ² inhibition and reninâ€“angiotensin system blockade: a pilot study. Canadian Journal of Physiology and Pharmacology, 2012, 90, 113-121.	1.4	9
151	Long-term hemodynamic and molecular effects persist after discontinued reninâ€“angiotensin system blockade in patients with type 1 diabetes mellitus. Kidney International, 2013, 84, 1246-1253.	5.2	9
152	Cross-sectional associations between central and general adiposity with albuminuria: observations from 400,000 people in UK Biobank. International Journal of Obesity, 2020, 44, 2256-2266.	3.4	9
153	Sodium-Glucose Cotransporter-2 Inhibitors in Nephrology Practice: A Narrative Review. Canadian Journal of Kidney Health and Disease, 2020, 7, 205435812093570.	1.1	9
154	Prucalopride-associated acute tubular necrosis. World Journal of Clinical Cases, 2014, 2, 380.	0.8	9
155	Potential Use of SGLT-2 Inhibitors in Obstructive Sleep Apnea: A new treatment on the horizon. Sleep and Breathing, 2023, 27, 77-89.	1.7	9
156	The effect of sex on humanin levels in healthy adults and patients with uncomplicated type 1 diabetes mellitus. Canadian Journal of Physiology and Pharmacology, 2015, 93, 239-243.	1.4	8
157	DAPA-CKD. JACC Basic To Translational Science, 2021, 6, 74-77.	4.1	8
158	Vasopressin associated with renal vascular resistance in adults with longstanding type 1 diabetes with and without diabetic kidney disease. Journal of Diabetes and Its Complications, 2021, 35, 107807.	2.3	8
159	Relationships between inflammation, hemodynamic function and RAAS in longstanding type 1 diabetes and diabetic kidney disease. Journal of Diabetes and Its Complications, 2021, 35, 107880.	2.3	8
160	Gender, clamped hyperglycemia and arterial stiffness in patients with uncomplicated type 1 diabetes mellitus. Clinical and Experimental Hypertension, 2014, 36, 187-193.	1.3	7
161	Tubuloglomerular Feedback in Renal Glucosuria: Mimicking Long-term SGLT-2 Inhibitor Therapy. Kidney Medicine, 2020, 2, 76-79.	2.0	7
162	A Unique Multi- and Interdisciplinary Cardiology-Renal-Endocrine Clinic: A Description and Assessment of Outcomes. Canadian Journal of Kidney Health and Disease, 2022, 9, 205435812210812.	1.1	7

#	Article	IF	Citations
163	Sex and Gender Related Differences in Diabetic Kidney Disease. Seminars in Nephrology, 2022, 42, 170-184.	1.6	7
164	Initial eGFR Changes with Ertugliflozin and Associations with Clinical Parameters: Analyses from the VERTIS CV Trial. American Journal of Nephrology, 2022, 53, 516-525.	3.1	7
165	Ability of Cystatin C to Detect Changes in Glomerular Filtration Rate After ACE Inhibition in Patients with Uncomplicated Type 1 Diabetes. Clinical and Experimental Hypertension, 2012, 34, 606-611.	1.3	6
166	Renal Hyperfiltration Is Associated With Glucose-Dependent Changes in Fractional Excretion of Sodium in Patients With Uncomplicated Type 1 Diabetes. Diabetes Care, 2014, 37, 2774-2781.	8.6	6
167	The urinary inflammatory profile in gluten free dietâ€"adherent adolescents with type 1 diabetes and celiac disease. Journal of Diabetes and Its Complications, 2016, 30, 295-299.	2.3	6
168	Beta cell preservation in patients with type 1 diabetes. Nature Medicine, 2018, 24, 1089-1090.	30.7	6
169	Evaluation of the Pharmacokinetics and Exposureâ€"Response Relationship of Dapagliflozin in Patients without Diabetes and with Chronic Kidney Disease. Clinical Pharmacokinetics, 2021, 60, 517-525.	3.5	6
170	Sodium-glucose cotransporter 2 inhibition in non-diabetic kidney disease. Current Opinion in Nephrology and Hypertension, 2021, 30, 474-481.	2.0	6
171	Cardiometabolic and Kidney Protection in Kidney Transplant Recipients With Diabetes: Mechanisms, Clinical Applications, and Summary of Clinical Trials. Transplantation, 2022, 106, 734-748.	1.0	6
172	Tubular injury in diabetic ketoacidosis: Results from the diabetic kidney alarm study. Pediatric Diabetes, 2021, 22, 1031-1039.	2.9	6
173	Atherosclerotic Cardiovascular Disease and Chronic Kidney Disease. Journal of the American College of Cardiology, 2019, 73, 2971-2975.	2.8	5
174	Renal haemodynamic response to sodiumâ€glucose cotransporterâ€2 inhibition does not depend on protein intake: An analysis of three randomized controlled trials. Diabetes, Obesity and Metabolism, 2021, 23, 1961-1967.	4.4	5
175	The association between physical activity time and neuropathy in longstanding type 1 diabetes: A cross-sectional analysis of the Canadian study of longevity in type 1 diabetes. Journal of Diabetes and Its Complications, 2022, 36, 108134.	2.3	5
176	The differential effects of ertugliflozin on glucosuria and natriuresis biomarkers: Prespecified analyses from <scp>VERTIS CV</scp>. Diabetes, Obesity and Metabolism, 2022, 24, 1114-1122.	4.4	5
177	Cardiorenal outcomes with ertugliflozin assessed according to baseline glucoseâ€lowering agent: An analysis from <scp>VERTIS CV</scp>. Diabetes, Obesity and Metabolism, 2022, , .	4.4	5
178	Sodiumâ€"glucose cotransporter 2 inhibitors as adjunct therapy for type 1 diabetes and the benefit on cardiovascular and renal disease evaluated by Steno risk engines. Journal of Diabetes and Its Complications, 2022, 36, 108257.	2.3	5
179	Risk factors for diabetic kidney disease in adults with longstanding type 1 diabetes: results from the Canadian Study of Longevity in Diabetes. Renal Failure, 2019, 41, 427-433.	2.1	4
180	Premature Death in Kidney Transplant Recipients: The Time for Trials is Now. Journal of the American Society of Nephrology: JASN, 2022, 33, 665-673.	6.1	4

#	Article	IF	Citations
181	Heart and Kidney Outcomes With Ertugliflozin in People with Non-albuminuric Diabetic Kidney Disease: A post hoc Analysis from the Randomized VERTIS CV Trial. Kidney International Reports, 2022, 7, 1782-1792.	0.8	4
182	SGLT2 Inhibition in Type 1 Diabetes with Diabetic Kidney Disease: Potential Cardiorenal Benefits Can Outweigh Preventable Risk of Diabetic Ketoacidosis. Current Diabetes Reports, 2022, 22, 317-332.	4.2	4
183	Calcium channel blockade blunts the renal effects of acute nitric oxide synthase inhibition in healthy humans. American Journal of Physiology - Renal Physiology, 2017, 312, F870-F878.	2.7	3
184	Biomarkers of Inflammation, Fibrosis, and Acute Kidney Injury in Patients with Heart Failure with and without Left Ventricular Assist Device Implantation. CardioRenal Medicine, 2019, 9, 108-116.	1.9	3
185	Allopurinol and Renal Outcomes in Adults With and Without Type 2 Diabetes: A Retrospective, Population-Based Cohort Study and Propensity Score Analysis. Canadian Journal of Diabetes, 2021, 45, 641-649.e4.	0.8	3
186	Case â€“ Reflex anuria: A rare complication of retrograde pyelography. Canadian Urological Association Journal, 2020, 15, E380-E382.	0.6	3
187	The effect of sex on endothelial function responses to clamped hyperglycemia in type 1 diabetes. Hypertension Research, 2014, 37, 220-224.	2.7	2
188	The Effect of SGLT2 Inhibition on Urinary Adenosine Excretion in Patients with Type 1 Diabetes. Canadian Journal of Diabetes, 2016, 40, S64.	0.8	2
189	MO051EFFECTS OF SEMAGLUTIDE ON CHRONIC KIDNEY DISEASE OUTCOMES: A POST HOC POOLED ANALYSIS FROM THE SUSTAIN 6 AND PIONEER 6 TRIALS. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	2
190	TO002REDUCTION IN THE RATE OF EGFR DECLINE WITH SEMAGLUTIDE VS PLACEBO: A POST HOC POOLED ANALYSIS OF SUSTAIN 6 AND PIONEER 6. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	2
191	126 - Prevalence of Detectable C-peptide in Longstanding Type 1 Diabetes (T1D). Canadian Journal of Diabetes, 2019, 43, S43.	0.8	1
192	LB005KIDNEY IMPLICATIONS OF THE INITIAL EGFR RESPONSE TO SGLT2 INHIBITION WITH EMPAGLIFLOZIN: THE â€˜EGFR DIPâ€™ IN EMPA-REG OUTCOME. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	1
193	SGLT2 Inhibition in Patients With Type 2 Diabetes Mellitus Post-Nephrectomy: A Single-Center Case Series. Canadian Journal of Kidney Health and Disease, 2021, 8, 205435812110655.	1.1	1
194	FC083: Finerenone and Canagliflozin in the Treatment of Chronic Kidney Disease and Type 2 Diabetes: Matching-Adjusted Indirect Treatment Comparison of Fidelio-DKD and Credence. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	1
195	Response to Comment on Lovshin et al. Dipeptidyl Peptidase 4 Inhibition Stimulates Distal Tubular Natriuresis and Increases in Circulating SDF-1Î± 1-67 in Patients With Type 2 Diabetes. Diabetes Care 2017;40:1073-1081. Diabetes Care, 2017, 40, e159-e160.	8.6	0
196	In Response. Anesthesia and Analgesia, 2018, 126, 1792-1793.	2.2	0
197	In Response. Anesthesia and Analgesia, 2018, 127, 307-308.	2.2	0
198	The authors reply. Kidney International, 2020, 97, 213-214.	5.2	0

#	Article	IF	Citations
199	Ertugliflozin, renoprotection and potential confounding by muscle wasting. Reply to Groothof D, Post A, Gans ROB et al [letter]. Diabetologia, 2022, 65, 908-911.	6.3	0